Circadian and sleep dysfunction in Alzheimer’s disease

@article{Uddin2020CircadianAS,
  title={Circadian and sleep dysfunction in Alzheimer’s disease},
  author={Md. Sahab Uddin and Devesh Tewari and Abdullah Al Mamun and Md. Tanvir Kabir and Kamal Niaz and Mir Imam Ibne Wahed and George E. Barreto and Ghulam Md. Ashraf},
  journal={Ageing Research Reviews},
  year={2020},
  volume={60}
}
Deciphering the Interacting Mechanisms of Circadian Disruption and Alzheimer's Disease.
TLDR
Analysis of the existing literature related to the molecular mechanisms of the circadian clock and interacting mechanisms of circadian disruption and AD pathogenesis finds that the interplay of circadian and sleep disturbances inducing AD progression is bidirectional.
Sleep, circadian rhythm and gut microbiota: alterations in Alzheimer’s disease and their potential links in the pathogenesis
TLDR
This review will provide an evaluation of clinical and animal studies describing GM alterations in distinct conditions, including AD, sleep and circadian disruption, to identify the overlapping and distinctiveGM alterations in these conditions and their contributions to pathophysiology.
Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease.
TLDR
This review represents the crucial and current research findings regarding the role of mTOR signaling in cognitive aging and cerebrovascular dysfunction in the pathogenesis of AD.
Hypothalamic gene network dysfunction is associated with cognitive decline and body weight loss in Alzheimer’s disease mice
TLDR
It is demonstrated that the new model of genetic diversity in AD, the AD-BXDs, exhibits non-cognitive symptoms consistent with hypothalamic dysfunction and Plek and Laptm5 are nominated as new targets to attenuate neuroinflammation in AD.
Exploring the Potential of Neuroproteomics in Alzheimer's Disease.
TLDR
The role of neuroproteomics is presented to analyze the complexity of AD to aid the prognosis, diagnosis, detection, and development of drug targets in AD.
Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer’s Disease
TLDR
A review of recent studies about the role of cannabinoids for the treatment of pain and related neuropathological changes in AD focuses on targeting the endocannabinoid system.
Impact of Pharmacotherapy on Insomnia in Patients with Alzheimer’s Disease
TLDR
Nonpharmacological approaches to treatment should be exhausted first and pharmacotherapy may be needed in certain clinical scenarios, which can be a challenge for clinicians given the paucity of evidence and guidelines for treatment in the subpopulation of Alzheimer’s disease.
Metabolic Profiling of Suprachiasmatic Nucleus Reveals Multifaceted Effects in an Alzheimer’s Disease Mouse Model
TLDR
The results suggest that redox disbalance and compromised GABA signaling are important denominators and connectors between neuroinflammation and clock dysfunction in AD.
...
...

References

SHOWING 1-10 OF 226 REFERENCES
Circadian Rhythm and Alzheimer’s Disease
TLDR
Following a pathophysiological reasoning backed by evidence gained from AD models, novel anti-inflammatory treatments and those targeting metabolic alterations in AD might prove useful for normalizing a disrupted circadian rhythm.
Sleep in Alzheimer's Disease–Beyond Amyloid
Melatonin in Alzheimer’s Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer’s Neuropathology
TLDR
The neuroprotective roles of melatonin are summarized by the blockage of Aβ production, Aβ oligomerization and fibrillation, tau hyperphosphorylation, synaptic dysfunction, oxidative stress, and neuronal death during AD progression.
Clinical management of sleep disturbances in Alzheimer’s disease: current and emerging strategies
TLDR
An update is presented on the role of sleep disorders in AD, the bidirectional influence of sleep problems and AD, and treatment options, raising the possibility that treating the sleep disorder may alter the course of the disease.
Sleep, circadian rhythms, and the pathogenesis of Alzheimer Disease
TLDR
The sleep–wake cycle appears to regulate levels of the pathogenic amyloid-beta peptide in the brain, and manipulating sleep can influence AD-related pathology in mouse models via multiple mechanisms.
Melatonin in Alzheimer’s Disease
TLDR
Interest is stimulated in melatonin as a potentially useful agent in the prevention and treatment of AD by demonstrating that melatonin efficiently attenuates Alzheimer-like tau hyperphosphorylation.
Circadian Disruption Associated with Alzheimer’s Disease
TLDR
Therapies including melatonin and bright light therapy may be advantageous in improving sleep and circadian rhythms and preventing the progression of disease, but these modalities are not curative, and additional research is needed to improve treatment options for these individuals.
Sleep Disorders Associated With Alzheimer's Disease: A Perspective
TLDR
Clinical features of sleep disorders in AD are described and the relation between sleep disorders and both cognitive impairment and poor prognosis of the disease is discussed.
Clinical Aspects of Melatonin Intervention in Alzheimer’s Disease Progression
TLDR
The analysis of published evidence made it possible to postulate melatonin as a useful ad-on therapeutic tool in MCI and larger randomized controlled trials are necessary to yield evidence of effectiveness before melatonin´s use can be advocated.
...
...